Back to search

Democritus University of Thrace (DUTH)

Ανάπτυξη και αξιολόγηση πειραματικού συστήματος κυτταρικής ανοσοθεραπείας του καρκίνου των ωοθηκών

Abstract

dc:description

T cell-based adoptive immunotherapy is a promising approach for the therapy of patients with advanced epithelial ovarian cancer (EOC). However, adoptive T cell therapy currently requires the isolation and characterization of rare antigen-specific T cells from each patient thus limiting its broad application. However, large amounts of tumor-reactive T cells with redirected specificity toward tumor associated antigens (TAA) can be generated following their genetic engineering with: A. Antigen-specific T cell receptors (TCRs) that bind to endogenously processed antigen-derived peptides that are presented by the major histocompatibility complex (MHC) molecules. B. Chimeric antigen receptors (CARs) that couple the high affinity binding of antibodies with the signaling domains of the T cell receptor and can bind to extracellular antigens in a non-MHC dependent manner.Ovarian cancers express a variety of TAA. Amongst those antigens ErbB2 (HER2/neu) represents an attractive candidate for the immunotherapy of cancer patients. However, the breadth of ErbB2 expression by primary human ovarian cancers remains controversial, which questions the suitability of this antigen for T cell based therapies. To address this issue, we performed extensive ErbB2 expression analysis on a wide panel of primary tumors as well as established and short-term human ovarian cancer cell lines. Sensitive detection methods including flow cytometry, western blot analysis and q-PCR revealed ErbB2 expression in all fresh tumor cells derived from primary ascites or solid tumors as well as all established cancer cell lines.In order to develop T cell immunotherapeutic strategies against ErbB2-expressing tumors we isolated a novel ErbB2-specific TCR from highly avid ErbB2-specific CD8+ T cells. T cells genetically modified to express the ErbB2 TCR recognized some ovarian tumor cell lines that efficiently processed and presented the ErbB2 peptide 369-377 through their MHC class I molecules (HLA-A2). In order to improve the targeting of ErbB2-expressing ovarian cancer and we sought toemploy CAR T cell therapy. Genetically-engineered human T cells expressing an ErbB2-specific chimeric antigen receptor (CAR) recognized and reacted against all established or primary ovarian cancer cells.For the development of immunotherapeutic approaches against other tumor antigens we constructed and evaluated a fully-human CAR with specificity for mesothelin which is widely expressed in EOC. Primary human T cells expressing the P4 CAR specifically produced exerted potent cytolytic functions when co-cultured with mesothelin-expressing tumors in vitro. Of note P4 CAR reactivity was not abrogated by soluble tumor-secreted or recombinant mesothelin protein even at supraphysiological levels. Importantly, adoptive transfer of P4 CAR-expressing T cells mediated the regression of large, established tumor in a xenogenic model of human ovarian cancer.A caveat of the P4 CAR approach is the possible on-target toxicity in normal mesothelial tissues that express low levels of mesothelin. To specify T cells for robust effector function that is selective for tumor but not normal tissue, we developed a trans-signaling CAR strategy that employs two CARs of differing antigen specificity; one recognizing mesothelin and the other the folate receptor alpha (FRα). T cells were simultaneously transduced with a CAR that provides suboptimal activation upon binding of mesothelin and a chimeric costimulatory receptor that recognizes a FRα. Trans-signaling CAR T cells demonstrated strong reactivity only against tumor cells co-expressing both antigens. Only weak reactivity was observed against mesothelin-expressing target cells both in vitro and in vivo. Thus, a dual specificity, trans-signaling CAR approach can potentiate the therapeutic efficacy of CAR T cells against cancer while minimizing "on target " toxicity against normal tissues bearing a single antigen.In summary, we have successfully constructed, developed and characterized physiological (TCR) and chimeric antigen receptors (CAR) of human origin. Finally to retain the powerful capacity of a conventional CAR T cell approach and increase the safety of the CAR T cells we developed a novel trans signaling CAR T cell platform. The above mentioned T cell engineering strategies will improve the anti-cancer effectiveness of T cell adoptive transfer therapies and inaugurate avenues for the successful treatment of ovarian cancer.

Degree

thesis:*
Grantor dc:publisher
Democritus University of Thrace (DUTH)
Year dc:date
2013

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Lanitis, Evripidis
  • Λανίτης, Ευριπίδης

Subjects

dc:subject × 22

Rights

Language dc:language
eng

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/28402

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Lanitis, Evripidis; Λανίτης, Ευριπίδης. Ανάπτυξη και αξιολόγηση πειραματικού συστήματος κυτταρικής ανοσοθεραπείας του καρκίνου των ωοθηκών. Democritus University of Thrace (DUTH), 2013. http://hdl.handle.net/10442/hedi/28402